Diabetes mellitus is a significant and growing health problem which contributes significantly to the prevalence of chronic kidney disease (CKD). According to the ERA-EDTA Registry, nearly a quarter (23 percent) of all patients who started renal replacement therapy in 2016 were patients with diabetes. The underlying idea of the study, which has been presented as a late breaking clinical trial at the ERA-EDTA congress in Budapest today, was to assess the potential of the DPP-4 inhibitor linagliptin (LINA), an oral diabetes drug, to reduce the burden of CKD and cardiac complications as secondary diseases in people with diabetes. Only a few weeks ago it had been shown that SGLT2 inhibitors, another class of diabetes drugs, could slow CKD progression in this patient group.
* This article was originally published here
